Literature DB >> 18378852

Novel exon 12 mutations in the HIF2A gene associated with erythrocytosis.

Melanie J Percy1, Philip A Beer, Gavin Campbell, Ad W Dekker, Anthony R Green, David Oscier, M Glenn Rainey, Richard van Wijk, Marion Wood, Terence R J Lappin, Mary Frances McMullin, Frank S Lee.   

Abstract

Erythrocytosis can arise from deregulation of the erythropoietin (Epo) axis resulting from defects in the oxygen-sensing pathway. Epo synthesis is controlled by the hypoxia inducible factor (HIF) complex, composed of an alpha and a beta subunit. There are 2 main alpha subunits, HIF-1 alpha and HIF-2 alpha. Recently, a HIF-2 alpha Gly537Trp mutation was identified in a family with erythrocytosis. This raises the possibility of HIF2A mutations being associated with other cases of erythrocytosis. We now report a subsequent analysis of HIF2A in a cohort of 75 erythrocytosis patients and identify 4 additional patients with novel heterozygous Met535Val and Gly537Arg mutations. All patients presented at a young age with elevated serum Epo. Mutations at Gly-537 account for 4 of 5 HIF2A mutations associated with erythrocytosis. These findings support the importance of HIF-2 alpha in human Epo regulation and warrant investigation of HIF2A in patients with unexplained erythrocytosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378852      PMCID: PMC2396730          DOI: 10.1182/blood-2008-02-137703

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.

Authors:  Sonny O Ang; Hua Chen; Kiichi Hirota; Victor R Gordeuk; Jaroslav Jelinek; Yongli Guan; Enli Liu; Adelina I Sergueeva; Galina Y Miasnikova; David Mole; Patrick H Maxwell; David W Stockton; Gregg L Semenza; Josef T Prchal
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

2.  Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling.

Authors:  Jung-Hyun Min; Haifeng Yang; Mircea Ivan; Frank Gertler; William G Kaelin; Nikola P Pavletich
Journal:  Science       Date:  2002-05-09       Impact factor: 47.728

3.  A conserved family of prolyl-4-hydroxylases that modify HIF.

Authors:  R K Bruick; S L McKnight
Journal:  Science       Date:  2001-10-11       Impact factor: 47.728

4.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Authors:  A C Epstein; J M Gleadle; L A McNeill; K S Hewitson; J O'Rourke; D R Mole; M Mukherji; E Metzen; M I Wilson; A Dhanda; Y M Tian; N Masson; D L Hamilton; P Jaakkola; R Barstead; J Hodgkin; P H Maxwell; C W Pugh; C J Schofield; P J Ratcliffe
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

5.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

6.  HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation.

Authors:  F Yu; S B White; Q Zhao; F S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

7.  Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.

Authors:  Wai-Ching Hon; Michael I Wilson; Karl Harlos; Timothy D W Claridge; Christopher J Schofield; Christopher W Pugh; Patrick H Maxwell; Peter J Ratcliffe; David I Stuart; E Yvonne Jones
Journal:  Nature       Date:  2002-06-05       Impact factor: 49.962

8.  Mutations in the VHL gene in sporadic apparently congenital polycythemia.

Authors:  Yves D Pastore; Jaroslav Jelinek; Sonny Ang; Yongli Guan; Enli Liu; Katerina Jedlickova; Lakshmanan Krishnamurti; Josef T Prchal
Journal:  Blood       Date:  2002-10-10       Impact factor: 22.113

9.  A gain-of-function mutation in the HIF2A gene in familial erythrocytosis.

Authors:  Melanie J Percy; Paul W Furlow; Guy S Lucas; Xiping Li; Terence R J Lappin; Mary Frances McMullin; Frank S Lee
Journal:  N Engl J Med       Date:  2008-01-10       Impact factor: 91.245

10.  Disturbance in the HIF-1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene.

Authors:  Maha Al-Sheikh; Kamran Moradkhani; Marc Lopez; Henri Wajcman; Claude Préhu
Journal:  Blood Cells Mol Dis       Date:  2007-10-15       Impact factor: 3.039

View more
  63 in total

1.  Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders.

Authors:  Cynthia M Beall; Gianpiero L Cavalleri; Libin Deng; Robert C Elston; Yang Gao; Jo Knight; Chaohua Li; Jiang Chuan Li; Yu Liang; Mark McCormack; Hugh E Montgomery; Hao Pan; Peter A Robbins; Kevin V Shianna; Siu Cheung Tam; Ngodrop Tsering; Krishna R Veeramah; Wei Wang; Puchung Wangdui; Michael E Weale; Yaomin Xu; Zhe Xu; Ling Yang; M Justin Zaman; Changqing Zeng; Li Zhang; Xianglong Zhang; Pingcuo Zhaxi; Yong Tang Zheng
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

2.  Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia.

Authors:  Charline Ladroue; David Hoogewijs; Sophie Gad; Romain Carcenac; Federica Storti; Michel Barrois; Anne-Paule Gimenez-Roqueplo; Michel Leporrier; Nicole Casadevall; Olivier Hermine; Jean-Jacques Kiladjian; André Baruchel; Fadi Fakhoury; Brigitte Bressac-de Paillerets; Jean Feunteun; Nathalie Mazure; Jacques Pouysségur; Roland H Wenger; Stéphane Richard; Betty Gardie
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

3.  Proteomic dissection of the von Hippel-Lindau (VHL) interactome.

Authors:  Yanlai Lai; Meihua Song; Kevin Hakala; Susan T Weintraub; Yuzuru Shiio
Journal:  J Proteome Res       Date:  2011-10-11       Impact factor: 4.466

4.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

5.  LINE-1 and EPAS1 DNA methylation associations with high-altitude exposure.

Authors:  Ainash Childebayeva; Tamara R Jones; Jaclyn M Goodrich; Fabiola Leon-Velarde; Maria Rivera-Chira; Melisa Kiyamu; Tom D Brutsaert; Dana C Dolinoy; Abigail W Bigham
Journal:  Epigenetics       Date:  2019-01-09       Impact factor: 4.528

6.  Nonmosaic somatic HIF2A mutations associated with late onset polycythemia-paraganglioma syndrome: Newly recognized subclass of polycythemia-paraganglioma syndrome.

Authors:  Ying Pang; Garima Gupta; Abhishek Jha; Xupeng Yue; Herui Wang; Thanh-Truc Huynh; Aiguo Li; Liping Li; Eva Baker; Emily Chew; Richard A Feelders; Esther Korpershoek; Zhengping Zhuang; Chunzhang Yang; Karel Pacak
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

7.  Erythrocytosis associated with a novel missense mutation in the HIF2A gene.

Authors:  Richard van Wijk; Scott Sutherland; Annet C W Van Wesel; Eric G Huizinga; Melanie J Percy; Marc Bierings; Frank S Lee
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

8.  Differential regulation of pulmonary vascular cell growth by hypoxia-inducible transcription factor-1α and hypoxia-inducible transcription factor-2α.

Authors:  Aftab Ahmad; Shama Ahmad; Kenneth C Malcolm; Stacy M Miller; Tara Hendry-Hofer; Jerome B Schaack; Carl W White
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

Review 9.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

10.  First report of bilateral pheochromocytoma in the clinical spectrum of HIF2A-related polycythemia-paraganglioma syndrome.

Authors:  David Taïeb; Chunzhang Yang; Blandine Delenne; Zhengping Zhuang; Anne Barlier; Fréderic Sebag; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.